Download person specification - consultant in medical oncology

CONSULTANT IN MEDICAL ONCOLOGY
with an interest in Gynaecological Malignancy, cancer of unknown primary and
Acute Oncology at Central Manchester University Hospitals.
1.
Background Information
This is a new post, supported by the Greater Manchester and Cheshire Cancer
Network and The Christie NHS Trust.
Candidates must by law be on the General Medical Council Specialist Register in
Medical Oncology or they must provide evidence that they will be on the register
by the time that they take up this appointment.
The purpose of the new post is to strengthen the Medical Oncology service for
patients living in the Greater Manchester and Cheshire Network, with particular
emphasis on Gynaecological Malignancy and cancer of unknown primary. In
addition this post will provide Acute Oncology input at Central Manchester
University Hospitals.
The successful applicant would become an active member of the Christie Lung
and Gynaecological Malignancy group, consisting of surgeons, clinical
oncologists and medical oncologists, pathologists, radiologists, nursing and allied
health professionals. The new consultant would be based at The Christie, but
would also work closely with the Gynaecological Malignancy team at Central
Manchester University Hospitals in terms of providing advice on systemic anticancer therapy and development pathways and treatment plans. The successful
applicant would be expected to develop/enhance systemic anti-cancer therapy
clinical trials activity at Central Manchester University Hospitals and The Christie
Hospital.
2.
The Christie NHS Foundation Trust
The Christie Hospital and Holt Radium Institute was founded in 1932 and has
grown to be the largest Cancer Hospital in the UK and one of the largest Cancer
Centres in Europe covering a large population in North West England. The Trust
is a designated teaching hospital of the University of Manchester and is the focal
point of the Regional Cancer Network. All cancer related specialties are fully
operational and more than 13,000 new patients with cancer are seen each year.
It is a major Cancer research centre and combined with University of
Manchester, the Paterson Institute for Cancer Research and Cancer Research
UK comprises the Manchester Cancer Research Centre.
The Trust is composed of three clinical management divisions Networked
Services Division – Director Professor Nick Slevin – includes the Departments of
1
Medical Oncology, Clinical Oncology, Haematology, Palliative Care, Paediatric
and Adolescent Oncology
Cancer Centre Services – Director – Miss Sarah O’Dwyer - Surgery,
Anaesthetics, HDU, Endocrinology and Haematology
Clinical Support Services – Director Dr Jeremy Lawrence - Radiology, Pathology,
Pharmacy, Supportive Care
Other support services are provided by the Corporate services Division including
Finance, Nursing & Operations and Estates & Facilities.
Both the Departments of Medical Oncology (Director: Dr Andrew Wardley) and
Clinical Oncology (Director: Dr John Logue), have international reputations for
their clinical work. Consultants are site specialised and common treatment
policies are developed through the multi-disciplinary Disease Groups (DGs).
Links to the cancer units are maintained through a number of peripheral and
outreach clinics across the Greater Manchester and Cheshire Cancer Network.
The Christie has developed two new satellite centre’s in the Pennine Trust and in
Salford so that ambulatory care can be can be delivered more locally.
The Christie expects to deliver in excess of 44,000 solid tumour chemotherapy
treatments in this financial year. The majority of chemotherapy treatments are
given as out-patient treatments in the Oak Road Treatment Centre at the main
Christie site. A small number of treatments are given as in-patient on three of the
wards at The Christie; we also provide a Haematology and Lymphoma service.
For those patients between the ages of 16 and 25, chemotherapy is administered
on our specialist Young Oncology Unit, tailored to the needs of this age group.
The Oak Road Treatment Centre is a purpose-built unit providing care for those
patients receiving outpatient chemotherapy and clinical trial treatments. It was
opened in November 2010 and in addition to chemotherapy delivery houses the
Phase I / II / III research facility and a private patient in-patient suite. Based on
The Christie Withington site, this unit presently provides the majority of outpatient
chemotherapy treatments for patients within the network. With 55 treatment
chairs and 27 beds the centre is the largest chemotherapy unit in the UK and the
largest single site clinical trials unit in the world.
Two hundred beds are in use at the Christie. The Department of Medical
Oncology beds are sited in 4 wards which are organised on a site group basis. A
medical admissions unit was opened in December 2007 to improve access for
clinical emergencies and provide immediate clinical care of non elective
admissions. The remainder of the beds are used for chemotherapy,
haematological oncology, endocrinology and surgery.
There is an adult outpatient department and separate facilities for minor surgical
procedures.
2
The Christie Hospital Department of Medical Oncology
The Christie Hospital Department of Medical Oncology has close links with The
University of Manchester. Dr. Andrew M. Wardley is Clinical Director of Medical
Oncology and Chemotherapy Services. There are 22 other Consultant grade
appointments in Medical Oncology. The Department of Medical Oncology is
actively involved in research and routine clinical work and in joint collaborative
programmes with the Department of Clinical Oncology in all aspects of oncology.
Clinical Oncology and Medical Oncology Consultants work closely together in
site specialised Disease Groups. The Christie Hospital Department of Medical
Oncology is one of the largest departments of cancer medicine in the NHS. The
major remit of the department is to develop improved methods for cancer patient
management. There are both clinical and laboratory scientific research
components that are closely integrated with clinical research and service work.
The Department has links with Preston Oncology Centre and with the
Department of Medical Oncology at Lancaster Royal Infirmary, which is included
as part of the Medical Oncology higher specialist training rotation (total 17
NTN’s).
The Department of Medical Oncology presently provides a service to Greater
Manchester and Cheshire, and parts of Lancashire, through regular clinics
(mainly weekly), staffed by its consultants (see appendix 1). The population of
the Christie’s catchment area is approximately 3.2 million. A total of 13,180 new
patients with cancer were seen by the Christie and associated clinics and 96958
radiotherapy fractions were delivered in 2011.
The Christie provides systemic anti-cancer therapy across the Greater
Manchester & Cheshire Cancer Network including at East Cheshire
(Macclesfield), Mid Cheshire (Leighton), Stockport, Pennine (Oldham) and
Tameside. Patients are reviewed by Christie consultants and treated by Christietrained staff on these sites. The Christie oncologists also provided systemic anticancer therapy advice to other trusts within the Greater Manchester & Cheshire
Cancer Network such as Macclesfield, Wigan and Bolton.
The Christie’s localising Chemotherapy Strategy 2012-15 approved by The
Christie board in March 2012 sets out the relocation of treatments so that 80% of
clinically appropriate treatments will be delivered at sites closer to patients’
homes. The Christie governance arrangements apply to all systemic anti-cancer
therapy treatments irrespective of the service provider, ensuring all patients
receive the best possible treatment, an excellent patient experience and that
recruitment to clinical trials continues to increase. These ambitious targets will
be met through the expansion of existing and new hospital settings and the use
of community based settings.
The Derek Crowther Early Phase Trial Unit and Oak Road Treatment Centre
The Derek Crowther Unit is a dedicated early phase clinical trials unit and it was
established on the Christie site in 2003. The subsequent development of the
Clinical Experimental Pharmacology group, GCLP compliant laboratories, the
Wolfson Medical Imaging Centre and the MCRC Biobank have complemented
this clinical infrastructure and over the last 8 years the Derek Crowther Unit has
3
flourished, doubling its research activity to more than 10,000 patient visits
annually. The unit presently supports over 100 clinical trials, recruits over 700
patients per annum to clinical research studies and collects over 18,000
biological research samples. A successful Clinical Research Infrastructure bid
has allowed a major programme of infrastructure expansion for clinical trials at
the Christie Hospital site and this will enable Manchester to become one of the
largest centres for early phase clinical trials worldwide. This infrastructure forms
part of the Oak Road Treatment Centre, a £35M development which includes
enlarged facilities for clinical and translational research, service chemotherapy,
pharmacy and private patients. The opening of the Oak Road Treatment Centre
in November 2010 is reinforced Manchester as one of the premier sites in the
world for conducting early phase clinical research.
Associated Departments
Clinical Oncology (Director Dr J Logue)
Clinical Oncology has 25 consultants and state of the art radiotherapy equipment
along with a major research centre - The Wade Centre (Director Dr John Logue).
The Clinical Oncology Division provides a service to Greater Manchester and
North Cheshire through clinics (mainly weekly) staffed by its consultants in every
main town in the area. A good liaison exists between the divisions of Clinical
Oncology and Medical Oncology. Many of the clinical protocols are run jointly
between the two departments and there are excellent opportunities at Specialist
Registrar level to participate in joint teaching programmes.
Haematological Oncology
Dr James Cavet, Dr Adrian Bloor and Dr Mike Dennis run a major transplant unit
with 18 dedicated beds.
Other Departments
The Department of Histopathology provides a regional cancer service.
The Department of Diagnostic Radiology has two whole body spiral CT scanners
and two MR scanners, in addition to standard radiological and radionuclide
imaging facilities. This department is currently undergoing major refurbishment,
and will be re-commissioned with new and more extensive equipment next year. A
PET-CT scanner was installed in early 2008.
The Department of Psychological Medicine is involved in collaborative research
projects concerning psychological assessment and counselling in the context of
clinical trials and is responsible for staff training in aspects of psychological
support.
Clinical and Laboratory Scientific Research
A wide range of clinical research studies are in progress. All disease groups have
research teams and are major contributors to national and international trials of
new treatments. These include Phase I/II and III systemic anti-cancer therapy
studies, combined surgery, radiotherapy and systemic anti-cancer therapy studies
and patient evaluation studies (staging procedures, psychological assessment
etc). A special interest is taken in the development of new biological therapies
4
particularly anti-angiogenic therapies (lead by Professor Gordon Jayson) and
gene/immunotherapies (led by Professor Robert Hawkins). Manchester has an
ECMC centre led by Professor Malcolm Ranson and has close links with the
Clinical Experimental Pharmacology laboratory led by Professor Caroline Dive.
There is a designated Early Phase Trials Unit (director Dr. Andrew M. Wardley)
where most clinical research activity occurs.
Administrative facilities
The post holder will have office accommodation with computer, intranet and
internet access at both sites. There will be secretarial support.
Ward facilities
1. General medical oncology wards – 40 inpatient beds available
2. 16 inpatient chemotherapy beds shared with Clinical Oncology.
3. The Haematology Transplant Unit (HTU), with 18 beds available for the care of
adult patients with haematological malignancy and lymphoma requiring
myeloablative therapy with haemopoietic rescue.
4. An 8 bedded Critical Care Unit opened in 2007.
A wide range of cancers are managed in these ward facilities and practical
training in all aspects of cancer medicine is provided at ST/SpR levels. Special
facilities include two cell separators for leukapheresis and plasmapheresis.
Outpatient facilities
Routine medical oncology clinics are held daily at the Christie Trust for new
patients and follow up. There are specialised cancer site related collaborative
clinics and routine outpatient clinics. Several of the Consultants visit DGH’s within
the Greater Manchester and Cheshire Cancer Network to undertake clinics for new
and follow-up patients. We are currently reviewing our outpatient facilities, and the
treatment and follow-up appointments, with a view to moving some of the activity to
Cancer Units in the network.
Specialist nurse facilities
Teams of specialist chemotherapy and research nurses work alongside the
clinicians. These nurses have special expertise and training in the administration of
chemotherapy. There are specialist nurses within each disease group. Specialist
nurses are also trained to insert central venous access devices, carry out bone
marrow aspiration/trephine procedures, operate the cell separators for
leukapheresis and provide psychological support and counselling. The Early Phase
Trials Unit recently appointed 2 advanced nurse practitioners to assessment with
management of trial patients.
5
3.
Details of the Post
It is envisaged that the post-holder would split their clinical commitments
between acute oncology and gynaecological cancers and would take a leading
role in the development of an acute oncology service which the post holder would
provide together with established consultant colleagues within other disease site
groups at Central Manchester University Hospitals. The post would be co-located
at Central Manchester University Hospitals and The Christie Withington site.
a).
Gynaecological Medical Oncology (GMO) Team
Professor Gordon Jayson, Dr Jurjees Hasan, Dr Andrew Clamp provide systemic
therapy for patients diagnosed with ovarian and endometrial cancer within the
Greater Manchester & Cheshire Cancer Network. Currently gynaecological
oncology surgery is provided at three sites within the Network (CMFT, SMUHT,
SRFT) each of which hosts a multidisciplinary team meeting. Complex pelvic
surgical procedures i.e. exenterative surgery is performed at The Christie. The
GMO team receives over 350 new referrals per year and provides second
opinions for cases from a wide geographical area. As well as clinical work, the
team plays a leading role in national and international early and late phase
clinical trial development in gynaecological cancers. We were the highest
recruiting centre to NCRN clinical studies in 2011-12 and also have a phase I
portfolio that focuses on novel anti-angiogenic agents.
This post will provide 2 clinical sessions to support the care of patients diagnosed
with gynaecological cancer in the North East sector alongside Dr Clamp and
Professor Jayson. It is anticipated that the post holder would attend the sector
MDT (located at CMFT once a fortnight alternating with a new patient clinic on
the Christie site. The second session would involve a chemotherapy/follow-up
clinic.
b).
Acute Oncology & Cancer of Unknown Primary
Central Manchester University Hospital NHS Foundation Trust are in
collaboration with The Christie is planning to implement an acute oncology
service. In view of the proximity of Central Manchester University Hospitals to
The Christie Hospital it does not provide systemic anti-cancer therapy on site but
it is a major acute hospital for Greater Manchester & Cheshire Cancer Network
with considerable need for acute oncology provision. It is envisaged that this post
will complement the current service which provides cancer-site specialised
support through the disease groups both at The Christie and within Central
Manchester University Hospital NHS Foundation Trust together with the current
Hotline clinic and the development of the Acute Oncology Network Office. This
post holder will lead a team of established consultants who are currently
providing the clinical aspects of the acute oncology service. This post holder
together with nursing support will formalise this service to provide dedicated and
comprehensive acute oncology support. The post-holder will be expected to lead
the cancer of unknown primary service at the centre and throughout the Greater
Manchester & Cheshire Cancer Network.
6
c).
Clinical Staff in Medical Oncology
The medical staff establishment provides for 23 Medical Oncology Consultants,
(see appendix 1) including academic consultants and 10 Specialist Registrars in
Medical Oncology. There is a junior doctor team at F2 and CMT level, working
jointly with Medical Oncology and Haematology, within the Division of Networked
Services.
d).
Duties of Post
The appointee will be based at The Christie Hospital and Central Manchester
University Hospital, NHS Foundation Trust and will be a member of the Medical
Oncology Consultant Group.
The post will involve the care of gynaecological cancer patients as defined
above.
The post holder will be required to conduct outpatient clinics involving
chemotherapy delivery, to supervise patients receiving chemotherapy and to
conduct ward rounds in a manner providing optimum patient care and efficient
use of the hospitals’ resources
The initial allocation of sessions if the appointment is full time is expected to be:
SERVICE
Location
Direct Clinical Care
Programmed Activity
Clinics at The Christie Hospital
2.5
MDT meetings
0.5
Acute Oncology
6
Including CUP activity (clinic &
multi-disciplinary team meeting
etc)
Supporting professional
1
Activities
(training, CPD, teaching, audit,
clinical governance, research,
appraisal
and
clinical
management)
Total
10 PAs
This may be altered in response to the requirements of the medical oncology
service in agreement with the Clinical Director of Medical Oncology.
7
The agreed work plan will be subject to annual review in line with Trust policy
and GMC revalidation. Appraisal in accordance with GMC revalidation will occur
annually. This will also include an assessment of professional development and
defined goals for the future. In the event of the consultant electing to work part
time a pro rata adjustment of fixed sessions would be anticipated. This will be
discussed and agreed with the division.
The department has evolved, over many years, a policy of mutual co-operation
between the consultants. The department consultant group meets monthly to
discuss joint management policies. Consultants are grouped in teams of two to
six supported by junior staff .The teams accept responsibility for agreed fields of
work and for cover for absence arrangements. All consultants are expected to
co-operate in these arrangements and to be involved in a number of clinical
areas of work.
A Clinical Director, Dr A Wardley, chairs the department. The Medical Oncology
Department works with the departments of clinical oncology, young oncology and
palliative care as part of the Network Services Division, with Jason Dawson as
Deputy Chief Operating Officer.
All consultants in the department share in an on-call rota that involves a
commitment to a full week in every four months. This covers the specialist
registrar who is second on-call. A Ward round every morning is expected so that
patients are reviewed within 24-hours of admission by a consultant. Consultants
provide advice on their area of expertise to all affiliated hospitals in the network
as required within the disease group that they work in and to provide emergency
advice as required to hospitals in the Greater Manchester & Cheshire Cancer
Network when on call.
The appointee will have office accommodation and access to a secretarial
service.
e).
Administration
The appointee will be a member of the Department of Medical Oncology
consultant group. The appointee will also be a member of The Christie medical
liaison and advisory group.
The clinical director within the consultant group negotiates administrative duties
within the Medical Oncology Department and consultants are expected to accept
responsibility for at least one area. This responsibility is regularly reviewed and
can be altered following consultation and agreement with the Director and
colleagues.
The present Executive Directors of the Trust are: Caroline Shaw
Ian Moston
Dr Chris Harrison
Jackie Bird
Roger Spencer
Chief Executive
Executive Director of Finance & Performance
Medical Director
Executive Director of Nursing & Governance
Chief Operating Officer
8
The Trust board is chaired by Lord K Bradley.
f).
Teaching
The Christie School of Oncology
The Christie Education Directorate provides undergraduate and postgraduate
education and training in oncology and palliative care to a wide spectrum of
professionals involved in the care of cancer patients. This will be in partnership
with the University of Manchester. The successful applicant would be expected to
play an important role in the activities of the Christie School of Oncology.
The department of medical oncology participates in the clinical undergraduate
teaching programme of the University of Manchester and students visit the
hospital for seminar, outpatients and bedside teaching at different stages in their
training. There are dedicated courses designed for postgraduate students
studying for the Part I and II examinations of the Fellowship of the Royal College
of Radiologists. Consultants are expected to participate in the specialist registrar
and F2 teaching programme.
Post-graduate training is co-ordinated by the Medical Oncology specialty training
group. The Training Programme Director in Medical Oncology is Dr Was
Mansoor. Undergraduate training is coordinated by Professor R A Cowan,
Director of Education.
The hospital has a Medical Library staffed by professional librarians offering a
range of services including a modern journal collection, extensive book library
and on line search facilities.
Education
• Promote excellence in learning and teaching and directly teach and mentor
undergraduate medical students for the university.
• Play a full role in postgraduate training of doctors and other professionals allied
to medicine
• Provide academic leadership and innovation in learning and teaching
• Contribute to leadership and coordination of quality assurance and
enhancement activities and preparations for review by external agencies.
g).
Particulars of Contract
Any consultant who is unable for personal reasons to work full-time will be
eligible to be considered for the post. The job content will be discussed on a
personal basis and agreed with the Trust.
h).
Job Planning
All job plans will be reviewed annually. The annual review will examine all
aspects of the job plan and should be carried out jointly by the Clinical Director
and the post holder.
9
THE CHRISTIE NHS FOUNDATION TRUST
TERMS AND CONDITIONS OF EMPLOYMENT
The terms and conditions of the New Consultant Contract are applicable
Salary:
Will be on the New Consultant Contract pay scale
Annual Leave:
0 - 7 years seniority
six weeks and 2 days per annum (pro rata for part time
employees)
7+ years seniority
six weeks and 4 days per annum (pro rata for part time
employees)
Bank Holiday:
8 public holidays
Resident:
The successful candidate will be required to live within a
reasonable travelling distance of the Trust.
Arrangements to visit the hospital may be made direct with the: Department of Medical Oncology
The Christie NHS Foundation Trust
Wilmslow Road
Withington
Manchester M20 4BX
Telephone number: 0161 446 8457
Clinical Director: Dr A Wardley
PA: [email protected]
Tel: 0161 446 3746
Gynaecological Malignancy enquiries
Prof Gordon Jayson
PA: Lisa Watmough
Tel: 0161 446 3606
10
Terms and Conditions of Service
PAY
The salary details for this post are based on the New Consultant Contract Terms and
Conditions.
You will have an honorary contract with the Christie Trust subject to appropriate
verification of qualifications, CRB checks and so on. This in turn means the following
conditions apply.
CONFIDENTIALITY
You must maintain the confidentiality of information about patients, staff and other health
service business.
HEALTH AND SAFETY
Employees must be aware of the responsibilities placed on them under the Health &
Safety at Work Act (1974), to ensure that the agreed safety procedures are carried out to
maintain a safe environment for employees.
RISK MANAGEMENT
All staff have a responsibility to report all clinical and non-clinical accidents or incidents
promptly and when requested to co-operate with any investigation undertaken.
EQUAL OPPORTUNITIES
The Trust has adopted an equal opportunities policy and it is the duty of every employee
to comply with the detail and spirit of the policy.
CONFLICT OF INTEREST
The Trust is responsible for the service for the patients in its care meets the highest
standards. Equally, it is responsible for ensuring that staff do not abuse their official
position to gain or to benefit their family or friends.
The Trust’s standing orders require any officer to declare any interest, direct or indirect
with contracts involving the Trust. Staff are not allowed to further their private interest in
the course of their NHS duties.
NO SMOKING
The Trust operates a no smoking policy.
MEDICAL EXAMINATION
All appointments with the Christie NHS Foundation Trust are subject to pre-employment
health screening.
11
APPENDIX 1
MEDICAL ONCOLOGY CONSULTANT STAFF
Clinical Staff
There are 23 consultants in the department of Medical Oncology:
Dr Anne Armstrong
Dr Fiona Blackhall
Dr Mike Braun
Dr Andrew Clamp
Dr. Rafaelle Colifano
Dr. Emma Dean
Dr Jurjees Hassan
Professor Robert Hawkins
Dr Richard Hubner
Professor Gordon Jayson
Dr Michael Leahy
Dr Kim Linton
Dr Paul Lorigan
Dr Was Mansoor
Dr Saifee Mullamitha
Professor John Radford
Professor Malcolm Ranson
Dr Yvonne Summers
Dr Paul Taylor
Dr Fiona Thistlethwaite
Professor Juan Valle
Dr Andrew Wardley,
Dr Greg Wilson
Breast Cancer – linking with Crewe
Lung Cancer
Colorectal – linking with Crewe College Tutor,
Gynaecologic Cancer
Lung- with University Hospital of South Manchester NSFT
Phase I and Melanoma
Colorectal and Ovarian
Renal, Gastric and Immunotherapy Phase I Trials
Upper GI and hepatobiliary
Ovarian Cancer and Anti-Angiogenesis Phase I Trials
Sarcoma and Teratoma, Clinical Director Young Oncology Unit
Lymphoma
Melanoma
Oesophago-Gastric/NET, TPD
Colorectal Cancer – link with Pennine Trust
Lymphoma, Clinical director R&D
Clinical Pharmacology, Phase I trials
Lung- with University Hospital of South Manchester NHSFT
Lung-with University Hospital of South Manchester NHSFT
Upper GI & Renal
Hepatobiliary and Neuroendocrine
Clinical Director of Medical Oncology and Chemotherapy
Services Clinical Director Early Phase Trials Unit, Breast
Cancer Consultant
Breast and Colorectal Cancer
There are at present ten Specialist Registrars, seven SHO level posts and 7 F2 doctors.
Eight Clinical Research Fellows also participate in clinical activities, in addition to their
laboratory research.
12
APPENDIX 2
PERSON SPECIFICATION - CONSULTANT IN MEDICAL ONCOLOGY
ATTAINMENTS
Education
ESSENTIAL
DESIRABLE
MB.ChB. or equivalent
Higher Degree MD. Ph.D
MRCP or equivalent
Training
Certificate of completed
specialist training or
equivalent (or within 6
months of CCT by
interview)
Postgraduate qualification
in Medical Education
Management experience
Research experience
Job experience
GENERAL
INTELLIGENCE
SPECIAL APTITUDES
INTERESTS
DISPOSITION
Acceptability
Appropriate experience in
Gynaecological Malignancy
oncology
Demonstrates knowledge,
logic and efficiency
Integrity, management and
communication skills
including teaching
Developments in oncology
practice
Knowledge of continuing
NHS and Royal College
Reforms.
Is a team player prepared
to adapt to changing
circumstances.
Leadership
Dynamic, decision-making
motivator.
Self-reliance
Confident in ability, but
knowing own limitations.
Motivation
Hardworking, enthusiastic
achiever.
Good attendance record.
Patient friendly.
Professional demeanour
Must be resilient and well
organised
13
Person Specification
REQUIREMENTS ESSENTIAL DESIRABLE
Qualifications
MB.ChB. or equivalent
MRCP or equivalent
Certificate of completed specialist training or equivalent (or within 6 months of CCT by
interview)
Training & Experience
Evidence of wide experience and training in general and oncological medicine and of
research
Demonstrated interest and experience in teaching/education
Attendance at “Teaching for Teachers” or equivalent
Experience of teaching undergraduate/postgraduate trainees
Evidence of involvement in hospital management
Has attended a management course
Academic / Research Achievements
Clinical and translational research experience.
Evidence of ability to provide academic leadership
Potential to progress to having an international research profile
Ability to apply for and be successful in being awarded peer reviewed grant income.
Recent articles in peer reviewed publications.
The ability to initiate, design and supervise clinical research.
Evidence of ongoing national/international research collaboration
Recipient of research award or prize
Ability to communicate and collaborate effectively with colleagues in other disciplines.
Ability to manage research projects
Ability to supervise postgraduate research students and assistants
Personal Skills
Demonstrable interpersonal skills.
Evidence of excellent written and oral communication skills.
Flexible approach to work.
The ability to work as part of a multi-disciplinary team.
Good time management skills, with the ability to prioritise and handle competing
demands.
Personal Circumstances
Reliable work record.
Good health record.
Living within reasonable travelling distance of The Christie
14
APPENDIX 3
B) University of Manchester
The University of Manchester
The University became the largest single site University in the UK in 2005 with the
merger of the Victoria University of Manchester and the University of Manchester
Institute of Science and Technology (UMIST). Currently approximately 40th in the world
rankings, it has an ambitious programme of development to become one of the top 25
universities in the world by 2015. Development is occurring University wide and cancer
is one of two areas selected for rapid development. It has significant existing activities in
cancer research within the Faculties of Medical and Human Sciences and Life Sciences.
The Faculty of Medical and Human Sciences
The Faculty is large and comprehensive, with all the important healthcare disciplines
represented in both research and teaching. Today, the Faculty has an annual research
income of £51M, almost a third of the University’s total research income.
There are 7,600 undergraduate students and 1,600 postgraduates on award-bearing
courses. More students graduate each year from the School of Medicine than from any
other medical school in the UK.
The Faculty’s goal for 2015 is to be a world leader in the translation of key elements of
biomedical research to patient care, working in collaboration with the NHS and industrial
partners.
The Manchester Academic Health Science Centre (MAHSC) is a partnership between
six NHS organisations in Greater Manchester and The University of Manchester. It is
based on a federal model and is the first AHSC in the UK to cover the full spectrum of
care (http://www.mahsc.ac.uk).
The School Cancer and Enabling Sciences in the Faculty of Medical and Human
Sciences
The focus for academic cancer medicine in the university is the Cancer and Enabling
Sciences Research School and has over 60 academic staff including 36 academic
clinicians. The jobholder will be based in the School. The total number of staff in the
Cancer Research Group is 140. Interests span from biomarker studies using clinical
proteomics and microarray analyses to advanced imaging within the Wolfson Molecular
Imaging
Centre
on
the
Christie
site,
and
elsewhere
(see
http://www.wmic.manchester.ac.uk/, http://www.bii.manchester.ac.uk/) . The School has
a first rate publication record in high impact medicine and cancer journals. The
development of close relations between the Christie NHS Foundation Trust underpins
future plans for research endeavours within the School. The School has a research
income of approximately £12m a year from industry, research councils and charities, a
23% increase on the previous year (2008/9).
The present management team is:
Professor Steve Williams Head of School and Head of the Imaging, Genomics &
Proteomics Research Group
Professor Vaskar Saha Head, Cancer Studies Research Group
15
The Faculty is currently undergoing a restructuring under the leadership of the Faculty
Dean, Professor Ian Jacobs. Cancer Studies will be refigured as a new Faculty Institute,
which will actively interact with researchers into cancer in other professional disciplines
such as Pharmacy and Nursing as well as with clinical colleagues.
The Paterson Institute for Cancer Research
The Institute is a leading cancer research institute funded by CR-UK. Research spans
the whole spectrum of cancer research, from programmes investigating the molecular
and cellular basis of cancer, to those focused on translational research and the
development of novel therapeutic approaches and experimental pharmacology.
The Institute works in close collaboration with The Christie NHS Foundation Trust and
the School.
Manchester Cancer Research Centre
The Manchester Cancer Research Centre (MCRC) was established in 2006 to bring
together the expertise, ambition and resources of partner organisations that already
have formidable individual reputations in the fields of cancer treatment and clinical
research. The partner organisations are The University of Manchester (including the
Paterson Institute for Cancer Research), The Christie NHS Foundation Trust and Cancer
Research UK.
The MCRC has outstanding facilities where researchers and clinicians can work closely
together. The joint aim is to gain a greater understanding of the fundamental basis of
how cancer develops and apply that knowledge to develop new diagnostic tests, new
treatments and better ways to predict outcomes in order to optimise treatment options
and care for cancer patients.
Recently new first class translational research facilities have been opened to support
current activities and develop into new areas such as molecular pathology. New
laboratories which meet Good Clinical Laboratory Practice standards have been
completed and commissioned and these improve our ability to assess clinical samples
from early phase trial patients under the strict regulations which are now required. These
activities are supported with major grants from the Experimental Cancer Medicines
Centre initiative and the Clinical Research Initiative, the latter allowing us to increase the
capacity for early phase clinical trials to world leading levels. In addition, the regional
tissue Biobank provides a valuable and accessible resource to underpin a diversity of
cancer research programmes.
Manchester has now been awarded Centre status by Cancer Research UK,
underpinning research and training on the Christie site and elsewhere
16
g)
Research
The Christie NHS Foundation Trust is committed to cancer research and recruits over
1900 patients per year to clinical trials. The Division of Clinical Research is led by
Professor John Radford, the Trust R&D Director. The largest Early Phase Trials Unit in
Europe was opened in November 2010. The Early Phase Trials Unit Director is Dr.
Andrew M. Wardley, was recently awarded a £4.5 Million grant from NIHR for clinical
research infrastructure.
Future projects include the development of a Molecular Diagnostics Unit, which has
already commenced, and £3.5m for the development of a Gene Therapy Centre. These,
along with other developments, will further enhance the research standing of the Trust.
Attached to The Christie is the University of Manchester Paterson Institute, an extensive
complex of laboratories supported by the Cancer Research UK (Director - Professor
Richard Marais). The Institute is dedicated to fundamental and clinically orientated
translational cancer research in many fields including radiobiology, haematology,
molecular biology, immunology, tumour chemotherapy and cytogenetics. A translational
research facility is being built. There are opportunities for clinical research in
developmental RT, chemo-radiotherapy and biological therapies.
17